<DOC>
	<DOCNO>NCT02345343</DOCNO>
	<brief_summary>The primary objective study report adverse event on-treatment AEs treating physician specify 24-month study period patient venous thromboembolism sentinel site ( ) National Center Pharmacovigilance ( CNFV ) Mexico .</brief_summary>
	<brief_title>Early Post-Marketing Study ELIQUIS ( Apixaban ) Mexico</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients 18 year old DVT PE sentinel site receive least 1 dose apixaban treatment and/or prevention recurrence DVT PE specify 24month study period Subjects receive apixaban part clinical trial Subjects receive apixaban indication local approve Contraindications include approve Mexican prescribe information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>